Chair
Member
Audit Committee Position

Robert Dickey IV, MBA*

Robert Dickey IV has experience as a CFO as well as in other C-level and Board positions in life sciences and medical device companies, both private and publicly-traded, across all stages of development. Before that, he was an investment banker, mostly at Lehman Brothers. He is currently a Managing Director at Foresite Advisors since March 2020 and was previously a Managing Director at Danforth Advisors from August 2018 to March 2020. Foresite Advisors provides finance support and strategy for life science companies, including strategic CFO advisory, financial analysis, capital raising, and transactional support/execution for public offerings and M&A. Mr. Dickey serves as a member of the board of directors at AngioGenex and served as a board member at Sanuthera, Inc., a privately held medical device company. Previously, he was CFO at Motif Bio PLC, a dual-listed, advanced stage antibiotics company. Mr. Dickey’s prior operating experience includes CFO at Tyme Technologies; CFO at NeoStem (now Caladrius Biosciences); SVP at Hemispherx; CFO and Business Unit Manager at StemCyte; and CEO and COO at Protarga. Mr. Dickey holds an M.B.A. from The Wharton School, University of Pennsylvania, and an A.B. from Princeton University.

Chair

Masaharu Osato, MD

Dr. Osato has been practicing gastroenterology and internal medicine ("GI") at his private practice, the Osato Medical Clinic, Inc. in Torrance, CA since 2001. He completed a GI Fellowship at the Harbor UCLA Medical Center and served as General Internist and Director of Health Screening Center at the Tokyo Adventist Hospital in Japan, as well as at the Kobe Adventist Hospital in Japan. He attended the Loma Linda University School of Medicine in California and completed an internal medicine residency at the Kettering Memorial Medical Center in Dayton, Ohio. Dr. Osato also completed one year of pediatric residency at the Loma Linda University Medical Center.

Member

Jane Pine Wood, JD

Ms. Wood has served since October 3, 2016 as Chief Legal Counsel of BioReference Laboratories, Inc., Elmwood Park, New Jersey, a wholly owned subsidiary of OPKO Health, Inc. (NASDAQ: OPK), a diversified healthcare company. BioReference Laboratories, Inc. is the nation’s third-largest clinical laboratory with a core genetic testing business and 400-person sales and marketing team. Ms. Wood has over 30 years of experience representing clinical and anatomic laboratories, physicians, imaging centers, home health agencies, mental health providers, hospitals, other healthcare providers, and professional societies in corporate, regulatory, reimbursement, contractual, and other matters. She holds a B.A. degree, summa cum laude, from Texas A&M University and a J.D. degree from Vanderbilt University School of Law and is a member of the State Bars of New Jersey, Massachusetts, Ohio, and Tennessee.

Member

Alfred Lui, MD

Dr. Lui is an anatomic and clinical pathologist with more than forty years of experience in the active practice of pathology and laboratory medicine. His personal professional corporation dba Innovative Pathology Medical Group was established in 2016. Prior to that time, he was the Laboratory Director for more numerous hospitals and independent clinical laboratories in Southern California and elsewhere. He currently serves as the Laboratory Director for privately-owned HalioDx, Marseille, France and Richmond, Virginia, and Bridge Diagnostics, Irvine, California, and for Lawrence Livermore National Laboratory, Livermore, California. He has founded or co-founded five medical companies and served as the Chairman of the Board, Chief Executive Officer and Laboratory Director of three of the companies. He currently serves as a member of the Board of Directors of two independent laboratory companies. He is a former-President, Board member, and current Education Committee member of the California Society of Pathologists. He is a Fellow of the College of American Pathologists (CAP) where he has served on multiple counsels and committees, including as a former Chair of the Publications Committee. He is a recipient of the CAP’s Distinguished Service award (2013) and the President’s Honors award (2015). He holds a B.A. degree from Andrews University and a M.D. from Loma Linda University. Dr. Lui’s qualifications as a director include his extensive experience as a director and Chief Executive Officer of numerous commercial medical laboratory companies..
Member

Audit Committee Charter

Download
Governance and Nominations Committee Position

Robert Dickey IV, MBA*

Robert Dickey IV has experience as a CFO as well as in other C-level and Board positions in life sciences and medical device companies, both private and publicly-traded, across all stages of development. Before that, he was an investment banker, mostly at Lehman Brothers. He is currently a Managing Director at Foresite Advisors since March 2020 and was previously a Managing Director at Danforth Advisors from August 2018 to March 2020. Foresite Advisors provides finance support and strategy for life science companies, including strategic CFO advisory, financial analysis, capital raising, and transactional support/execution for public offerings and M&A. Mr. Dickey serves as a member of the board of directors at AngioGenex and served as a board member at Sanuthera, Inc., a privately held medical device company. Previously, he was CFO at Motif Bio PLC, a dual-listed, advanced stage antibiotics company. Mr. Dickey’s prior operating experience includes CFO at Tyme Technologies; CFO at NeoStem (now Caladrius Biosciences); SVP at Hemispherx; CFO and Business Unit Manager at StemCyte; and CEO and COO at Protarga. Mr. Dickey holds an M.B.A. from The Wharton School, University of Pennsylvania, and an A.B. from Princeton University.

Member

Jane Pine Wood, JD

Ms. Wood has served since October 3, 2016 as Chief Legal Counsel of BioReference Laboratories, Inc., Elmwood Park, New Jersey, a wholly owned subsidiary of OPKO Health, Inc. (NASDAQ: OPK), a diversified healthcare company. BioReference Laboratories, Inc. is the nation’s third-largest clinical laboratory with a core genetic testing business and 400-person sales and marketing team. Ms. Wood has over 30 years of experience representing clinical and anatomic laboratories, physicians, imaging centers, home health agencies, mental health providers, hospitals, other healthcare providers, and professional societies in corporate, regulatory, reimbursement, contractual, and other matters. She holds a B.A. degree, summa cum laude, from Texas A&M University and a J.D. degree from Vanderbilt University School of Law and is a member of the State Bars of New Jersey, Massachusetts, Ohio, and Tennessee.

Chair

Wei Peu Zen, MBA

Mr. Zen is Vice Chairman and Chief Executive Officer of Wai Kee Holdings Limited., a Hong Kong-based construction and infrastructure company whose shares are listed on the Main Board of the Hong Kong Stock Exchange Limited. He is also the Chairman of Build King Holdings Limited and Chairman of Road King Infrastructure Limited, both of which are subsidiaries of Wai Kee Holdings Limited. Mr. Zen has over 45 years of experience in civil engineering, and is responsible for the overall management of the Wai Kee Holdings Limited group of companies. He oversees the operations of the group’s construction, quarry and concrete divisions. Mr. Zen holds a B.Sc. degree in Engineering from The University of Hong Kong and a M.B.A. from The Chinese University of Hong Kong and is a member of both the Institution of Civil Engineers and fellow member of the Hong Kong Institution of Engineers and the Institute of Quarrying, UK, respectively. He is a past Honorary Treasurer of the Hong Kong Construction Association and a member of HKTDC Infrastructure Development Advisory Committee. He is also the President of the Hong Kong Contract Bridge Association.

Member

Governance and Nominations Committee Charter

Download
Compensation Committee Position

Robert Dickey IV, MBA*

Robert Dickey IV has experience as a CFO as well as in other C-level and Board positions in life sciences and medical device companies, both private and publicly-traded, across all stages of development. Before that, he was an investment banker, mostly at Lehman Brothers. He is currently a Managing Director at Foresite Advisors since March 2020 and was previously a Managing Director at Danforth Advisors from August 2018 to March 2020. Foresite Advisors provides finance support and strategy for life science companies, including strategic CFO advisory, financial analysis, capital raising, and transactional support/execution for public offerings and M&A. Mr. Dickey serves as a member of the board of directors at AngioGenex and served as a board member at Sanuthera, Inc., a privately held medical device company. Previously, he was CFO at Motif Bio PLC, a dual-listed, advanced stage antibiotics company. Mr. Dickey’s prior operating experience includes CFO at Tyme Technologies; CFO at NeoStem (now Caladrius Biosciences); SVP at Hemispherx; CFO and Business Unit Manager at StemCyte; and CEO and COO at Protarga. Mr. Dickey holds an M.B.A. from The Wharton School, University of Pennsylvania, and an A.B. from Princeton University.

Member

Jane Pine Wood, JD

Ms. Wood has served since October 3, 2016 as Chief Legal Counsel of BioReference Laboratories, Inc., Elmwood Park, New Jersey, a wholly owned subsidiary of OPKO Health, Inc. (NASDAQ: OPK), a diversified healthcare company. BioReference Laboratories, Inc. is the nation’s third-largest clinical laboratory with a core genetic testing business and 400-person sales and marketing team. Ms. Wood has over 30 years of experience representing clinical and anatomic laboratories, physicians, imaging centers, home health agencies, mental health providers, hospitals, other healthcare providers, and professional societies in corporate, regulatory, reimbursement, contractual, and other matters. She holds a B.A. degree, summa cum laude, from Texas A&M University and a J.D. degree from Vanderbilt University School of Law and is a member of the State Bars of New Jersey, Massachusetts, Ohio, and Tennessee.

Member

Alfred Lui, MD

Dr. Lui is an anatomic and clinical pathologist with more than forty years of experience in the active practice of pathology and laboratory medicine. His personal professional corporation dba Innovative Pathology Medical Group was established in 2016. Prior to that time, he was the Laboratory Director for more numerous hospitals and independent clinical laboratories in Southern California and elsewhere. He currently serves as the Laboratory Director for privately-owned HalioDx, Marseille, France and Richmond, Virginia, and Bridge Diagnostics, Irvine, California, and for Lawrence Livermore National Laboratory, Livermore, California. He has founded or co-founded five medical companies and served as the Chairman of the Board, Chief Executive Officer and Laboratory Director of three of the companies. He currently serves as a member of the Board of Directors of two independent laboratory companies. He is a former-President, Board member, and current Education Committee member of the California Society of Pathologists. He is a Fellow of the College of American Pathologists (CAP) where he has served on multiple counsels and committees, including as a former Chair of the Publications Committee. He is a recipient of the CAP’s Distinguished Service award (2013) and the President’s Honors award (2015). He holds a B.A. degree from Andrews University and a M.D. from Loma Linda University. Dr. Lui’s qualifications as a director include his extensive experience as a director and Chief Executive Officer of numerous commercial medical laboratory companies..
Member

Compensation Committee Charter

Download

*Financial Expert

Robert Dickey IV, MBA

Robert Dickey IV has experience as a CFO as well as in other C-level and Board positions in life sciences and medical device companies, both private and publicly-traded, across all stages of development. Before that, he was an investment banker, mostly at Lehman Brothers. He is currently a Managing Director at Foresite Advisors since March 2020 and was previously a Managing Director at Danforth Advisors from August 2018 to March 2020. Foresite Advisors provides finance support and strategy for life science companies, including strategic CFO advisory, financial analysis, capital raising, and transactional support/execution for public offerings and M&A. Mr. Dickey serves as a member of the board of directors at AngioGenex and served as a board member at Sanuthera, Inc., a privately held medical device company. Previously, he was CFO at Motif Bio PLC, a dual-listed, advanced stage antibiotics company. Mr. Dickey’s prior operating experience includes CFO at Tyme Technologies; CFO at NeoStem (now Caladrius Biosciences); SVP at Hemispherx; CFO and Business Unit Manager at StemCyte; and CEO and COO at Protarga. Mr. Dickey holds an M.B.A. from The Wharton School, University of Pennsylvania, and an A.B. from Princeton University.

Masaharu Osato, MD

Dr. Osato has been practicing gastroenterology and internal medicine ("GI") at his private practice, the Osato Medical Clinic, Inc. in Torrance, CA since 2001. He completed a GI Fellowship at the Harbor UCLA Medical Center and served as General Internist and Director of Health Screening Center at the Tokyo Adventist Hospital in Japan, as well as at the Kobe Adventist Hospital in Japan. He attended the Loma Linda University School of Medicine in California and completed an internal medicine residency at the Kettering Memorial Medical Center in Dayton, Ohio. Dr. Osato also completed one year of pediatric residency at the Loma Linda University Medical Center.

Jane Pine Wood, JD

Ms. Wood has served since October 3, 2016 as Chief Legal Counsel of BioReference Laboratories, Inc., Elmwood Park, New Jersey, a wholly owned subsidiary of OPKO Health, Inc. (NASDAQ: OPK), a diversified healthcare company. BioReference Laboratories, Inc. is the nation’s third-largest clinical laboratory with a core genetic testing business and 400-person sales and marketing team. Ms. Wood has over 30 years of experience representing clinical and anatomic laboratories, physicians, imaging centers, home health agencies, mental health providers, hospitals, other healthcare providers, and professional societies in corporate, regulatory, reimbursement, contractual, and other matters. She holds a B.A. degree, summa cum laude, from Texas A&M University and a J.D. degree from Vanderbilt University School of Law and is a member of the State Bars of New Jersey, Massachusetts, Ohio, and Tennessee.

Alfred Lui, MD

Dr. Lui is an anatomic and clinical pathologist with more than forty years of experience in the active practice of pathology and laboratory medicine. His personal professional corporation dba Innovative Pathology Medical Group was established in 2016. Prior to that time, he was the Laboratory Director for more numerous hospitals and independent clinical laboratories in Southern California and elsewhere. He currently serves as the Laboratory Director for privately-owned HalioDx, Marseille, France and Richmond, Virginia, and Bridge Diagnostics, Irvine, California, and for Lawrence Livermore National Laboratory, Livermore, California. He has founded or co-founded five medical companies and served as the Chairman of the Board, Chief Executive Officer and Laboratory Director of three of the companies. He currently serves as a member of the Board of Directors of two independent laboratory companies. He is a former-President, Board member, and current Education Committee member of the California Society of Pathologists. He is a Fellow of the College of American Pathologists (CAP) where he has served on multiple counsels and committees, including as a former Chair of the Publications Committee. He is a recipient of the CAP’s Distinguished Service award (2013) and the President’s Honors award (2015). He holds a B.A. degree from Andrews University and a M.D. from Loma Linda University. Dr. Lui’s qualifications as a director include his extensive experience as a director and Chief Executive Officer of numerous commercial medical laboratory companies..

Robert Dickey IV, MBA

Robert Dickey IV has experience as a CFO as well as in other C-level and Board positions in life sciences and medical device companies, both private and publicly-traded, across all stages of development. Before that, he was an investment banker, mostly at Lehman Brothers. He is currently a Managing Director at Foresite Advisors since March 2020 and was previously a Managing Director at Danforth Advisors from August 2018 to March 2020. Foresite Advisors provides finance support and strategy for life science companies, including strategic CFO advisory, financial analysis, capital raising, and transactional support/execution for public offerings and M&A. Mr. Dickey serves as a member of the board of directors at AngioGenex and served as a board member at Sanuthera, Inc., a privately held medical device company. Previously, he was CFO at Motif Bio PLC, a dual-listed, advanced stage antibiotics company. Mr. Dickey’s prior operating experience includes CFO at Tyme Technologies; CFO at NeoStem (now Caladrius Biosciences); SVP at Hemispherx; CFO and Business Unit Manager at StemCyte; and CEO and COO at Protarga. Mr. Dickey holds an M.B.A. from The Wharton School, University of Pennsylvania, and an A.B. from Princeton University.

Jane Pine Wood, JD

Ms. Wood has served since October 3, 2016 as Chief Legal Counsel of BioReference Laboratories, Inc., Elmwood Park, New Jersey, a wholly owned subsidiary of OPKO Health, Inc. (NASDAQ: OPK), a diversified healthcare company. BioReference Laboratories, Inc. is the nation’s third-largest clinical laboratory with a core genetic testing business and 400-person sales and marketing team. Ms. Wood has over 30 years of experience representing clinical and anatomic laboratories, physicians, imaging centers, home health agencies, mental health providers, hospitals, other healthcare providers, and professional societies in corporate, regulatory, reimbursement, contractual, and other matters. She holds a B.A. degree, summa cum laude, from Texas A&M University and a J.D. degree from Vanderbilt University School of Law and is a member of the State Bars of New Jersey, Massachusetts, Ohio, and Tennessee.

Wei Peu Zen, MBA

Mr. Zen is Vice Chairman and Chief Executive Officer of Wai Kee Holdings Limited., a Hong Kong-based construction and infrastructure company whose shares are listed on the Main Board of the Hong Kong Stock Exchange Limited. He is also the Chairman of Build King Holdings Limited and Chairman of Road King Infrastructure Limited, both of which are subsidiaries of Wai Kee Holdings Limited. Mr. Zen has over 45 years of experience in civil engineering, and is responsible for the overall management of the Wai Kee Holdings Limited group of companies. He oversees the operations of the group’s construction, quarry and concrete divisions. Mr. Zen holds a B.Sc. degree in Engineering from The University of Hong Kong and a M.B.A. from The Chinese University of Hong Kong and is a member of both the Institution of Civil Engineers and fellow member of the Hong Kong Institution of Engineers and the Institute of Quarrying, UK, respectively. He is a past Honorary Treasurer of the Hong Kong Construction Association and a member of HKTDC Infrastructure Development Advisory Committee. He is also the President of the Hong Kong Contract Bridge Association.

Robert Dickey IV, MBA

Robert Dickey IV has experience as a CFO as well as in other C-level and Board positions in life sciences and medical device companies, both private and publicly-traded, across all stages of development. Before that, he was an investment banker, mostly at Lehman Brothers. He is currently a Managing Director at Foresite Advisors since March 2020 and was previously a Managing Director at Danforth Advisors from August 2018 to March 2020. Foresite Advisors provides finance support and strategy for life science companies, including strategic CFO advisory, financial analysis, capital raising, and transactional support/execution for public offerings and M&A. Mr. Dickey serves as a member of the board of directors at AngioGenex and served as a board member at Sanuthera, Inc., a privately held medical device company. Previously, he was CFO at Motif Bio PLC, a dual-listed, advanced stage antibiotics company. Mr. Dickey’s prior operating experience includes CFO at Tyme Technologies; CFO at NeoStem (now Caladrius Biosciences); SVP at Hemispherx; CFO and Business Unit Manager at StemCyte; and CEO and COO at Protarga. Mr. Dickey holds an M.B.A. from The Wharton School, University of Pennsylvania, and an A.B. from Princeton University.

Jane Pine Wood, JD

Ms. Wood has served since October 3, 2016 as Chief Legal Counsel of BioReference Laboratories, Inc., Elmwood Park, New Jersey, a wholly owned subsidiary of OPKO Health, Inc. (NASDAQ: OPK), a diversified healthcare company. BioReference Laboratories, Inc. is the nation’s third-largest clinical laboratory with a core genetic testing business and 400-person sales and marketing team. Ms. Wood has over 30 years of experience representing clinical and anatomic laboratories, physicians, imaging centers, home health agencies, mental health providers, hospitals, other healthcare providers, and professional societies in corporate, regulatory, reimbursement, contractual, and other matters. She holds a B.A. degree, summa cum laude, from Texas A&M University and a J.D. degree from Vanderbilt University School of Law and is a member of the State Bars of New Jersey, Massachusetts, Ohio, and Tennessee.

Alfred Lui, MD

Dr. Lui is an anatomic and clinical pathologist with more than forty years of experience in the active practice of pathology and laboratory medicine. His personal professional corporation dba Innovative Pathology Medical Group was established in 2016. Prior to that time, he was the Laboratory Director for more numerous hospitals and independent clinical laboratories in Southern California and elsewhere. He currently serves as the Laboratory Director for privately-owned HalioDx, Marseille, France and Richmond, Virginia, and Bridge Diagnostics, Irvine, California, and for Lawrence Livermore National Laboratory, Livermore, California. He has founded or co-founded five medical companies and served as the Chairman of the Board, Chief Executive Officer and Laboratory Director of three of the companies. He currently serves as a member of the Board of Directors of two independent laboratory companies. He is a former-President, Board member, and current Education Committee member of the California Society of Pathologists. He is a Fellow of the College of American Pathologists (CAP) where he has served on multiple counsels and committees, including as a former Chair of the Publications Committee. He is a recipient of the CAP’s Distinguished Service award (2013) and the President’s Honors award (2015). He holds a B.A. degree from Andrews University and a M.D. from Loma Linda University. Dr. Lui’s qualifications as a director include his extensive experience as a director and Chief Executive Officer of numerous commercial medical laboratory companies..